Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers

on behalf of IPMDS-Neuroimaging Study Group

doi:10.1002/mds.26907

Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers

on behalf of IPMDS-Neuroimaging Study Group

Research output: Contribution to journal › Review article › peer-review

97 Citations (Scopus)

Abstract

Molecular imaging has proven to be a powerful tool for investigation of parkinsonian disorders. One current challenge is to identify biomarkers of early changes that may predict the clinical trajectory of parkinsonian disorders. Exciting new tracer developments hold the potential for in vivo markers of underlying pathology. Herein, we provide an overview of molecular imaging advances and how these approaches help us to understand PD and atypical parkinsonisms.

Original language	English
Pages (from-to)	181-192
Number of pages	12
Journal	Movement Disorders
Volume	32
Issue number	2
DOIs	https://doi.org/10.1002/mds.26907
Publication status	Published - 01-02-2017
Externally published	Yes

All Science Journal Classification (ASJC) codes

Neurology
Clinical Neurology

Access to Document

10.1002/mds.26907

Cite this

@article{91ffd52887da40c89c8f911035d7c39c,

title = "Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers",

abstract = "Molecular imaging has proven to be a powerful tool for investigation of parkinsonian disorders. One current challenge is to identify biomarkers of early changes that may predict the clinical trajectory of parkinsonian disorders. Exciting new tracer developments hold the potential for in vivo markers of underlying pathology. Herein, we provide an overview of molecular imaging advances and how these approaches help us to understand PD and atypical parkinsonisms.",

keywords = "FDG, PET, Parkinson's disease, acetylcholine, amyloid, atypical parkinsonism, dopamine, serotonin, tau",

author = "\{on behalf of IPMDS-Neuroimaging Study Group\} and Strafella, \{Antonio P.\} and Bohnen, \{Nicolaas I.\} and Perlmutter, \{Joel S.\} and David Eidelberg and Nicola Pavese and \{Van Eimeren\}, Thilo and Paola Piccini and Marios Politis and Stephane Thobois and Roberto Ceravolo and Makoto Higuchi and Valtteri Kaasinen and Mario Masellis and Peralta, \{M. Cecilia\} and Ignacio Obeso and Pineda-Pardo, \{Jose {\'A}ngel\} and Roberto Cilia and Benedicte Ballanger and Martin Niethammer and Stoessl, \{Jon A.\}",

note = "Publisher Copyright: {\textcopyright} 2016 International Parkinson and Movement Disorder Society",

year = "2017",

month = feb,

day = "1",

doi = "10.1002/mds.26907",

language = "English",

volume = "32",

pages = "181--192",

journal = "Movement Disorders",

issn = "0885-3185",

publisher = "John Wiley \& Sons Inc.",

number = "2",

}

TY - JOUR

T1 - Molecular imaging to track Parkinson's disease and atypical parkinsonisms

T2 - New imaging frontiers

AU - on behalf of IPMDS-Neuroimaging Study Group

AU - Strafella, Antonio P.

AU - Bohnen, Nicolaas I.

AU - Perlmutter, Joel S.

AU - Eidelberg, David

AU - Pavese, Nicola

AU - Van Eimeren, Thilo

AU - Piccini, Paola

AU - Politis, Marios

AU - Thobois, Stephane

AU - Ceravolo, Roberto

AU - Higuchi, Makoto

AU - Kaasinen, Valtteri

AU - Masellis, Mario

AU - Peralta, M. Cecilia

AU - Obeso, Ignacio

AU - Pineda-Pardo, Jose Ángel

AU - Cilia, Roberto

AU - Ballanger, Benedicte

AU - Niethammer, Martin

AU - Stoessl, Jon A.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Molecular imaging has proven to be a powerful tool for investigation of parkinsonian disorders. One current challenge is to identify biomarkers of early changes that may predict the clinical trajectory of parkinsonian disorders. Exciting new tracer developments hold the potential for in vivo markers of underlying pathology. Herein, we provide an overview of molecular imaging advances and how these approaches help us to understand PD and atypical parkinsonisms.

AB - Molecular imaging has proven to be a powerful tool for investigation of parkinsonian disorders. One current challenge is to identify biomarkers of early changes that may predict the clinical trajectory of parkinsonian disorders. Exciting new tracer developments hold the potential for in vivo markers of underlying pathology. Herein, we provide an overview of molecular imaging advances and how these approaches help us to understand PD and atypical parkinsonisms.

KW - FDG

KW - PET

KW - Parkinson's disease

KW - acetylcholine

KW - amyloid

KW - atypical parkinsonism

KW - dopamine

KW - serotonin

KW - tau

UR - https://www.scopus.com/pages/publications/85011698068

UR - https://www.scopus.com/pages/publications/85011698068#tab=citedBy

U2 - 10.1002/mds.26907

DO - 10.1002/mds.26907

M3 - Review article

C2 - 28150432

AN - SCOPUS:85011698068

SN - 0885-3185

VL - 32

SP - 181

EP - 192

JO - Movement Disorders

JF - Movement Disorders

IS - 2

ER -

Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this